Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

<p>Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million milestone payment earned under the AZSTARYS® license agreement Ended Q2 2023 with $87.4 million in cash, cash equivalents, and investments, supporting our forecasted cash runway […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/zevra-therapeutics-reports-corporate-updates-and-second-quarter-2023-financial-results/">Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>